We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor.
- Authors
Dotsu, Yosuke; Yamaguchi, Hiroyuki; Fukuda, Minoru; Suyama, Takayuki; Honda, Noritaka; Umeyama, Yasuhiro; Taniguchi, Hirokazu; Gyotoku, Hiroshi; Takemoto, Shinnosuke; Tagawa, Ryuta; Ogata, Ryosuke; Tomono, Hiromi; Shimada, Midori; Senju, Hiroaki; Nakatomi, Katsumi; Nagashima, Seiji; Soda, Hiroshi; Ikeda, Hiroaki; Ashizawa, Kazuto; Mukae, Hiroshi
- Abstract
Background: Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression. Purpose: The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-agent amrubicin chemotherapy for thoracic malignancies. Patients and methods: The medical records of consecutive patients with thoracic malignancies, including SCLC and non-small cell lung cancer (NSCLC), who were treated with single-agent amrubicin chemotherapy in cycle 1 between January 2010 and March 2020, were retrospectively analyzed. Results: One hundred and fifty-six patients from four institutions were enrolled. Their characteristics were as follows: median age (range): 68 (32–86); male/female: 126/30; performance status (0/1/2): 9/108/39; SCLC/NSCLC/others: 111/30/15; and prior treatment (0/1/2/3-): 1/96/31/28. One hundred and thirty-four (86%) and 97 (62%) patients experienced grade 3/4 and grade 4 neutropenia, respectively. One hundred and twelve patients (72%) required therapeutic G-CSF treatment, and 47 (30%) developed FN. Prophylactic PEG-G-CSF was not used in cycle 1 in any case. The median overall survival of the patients with FN was significantly shorter than that of the patients without FN (7.2 vs. 10.0 months, p = 0.025). Conclusions: The real-world incidence rate of FN among patients with thoracic malignancies that were treated with single-agent amrubicin chemotherapy was 30%. It is suggested that prophylactic G-CSF should be administered during the practical use of single-agent amrubicin chemotherapy for patients who have already received chemotherapy.
- Subjects
GRANULOCYTE-colony stimulating factor; FEBRILE neutropenia; SMALL cell lung cancer; NON-small-cell lung carcinoma; OVERALL survival; SURVIVAL rate
- Publication
Journal of Clinical Medicine, 2021, Vol 10, Issue 18, p4221
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm10184221